A method for preparing platelet-rich plasma without exogenous additives

Abstract

The invention relates to a method for preparing platelet-rich plasma without exogenous additives. The platelet-rich plasma preparation method of the present invention comprises the following steps: sample preparation: adding venous whole blood into a pre-cooled centrifuge tube; first centrifugation: first centrifuging venous whole blood, 180g, 10 minutes; the second centrifugation: transfer the plasma layer to a new centrifuge tube, balance, and perform the second centrifugation, 1550g, 10 minutes; discard the plasma supernatant after centrifugation, and retain 1 / 10 of the volume of venous whole blood The platelet-rich plasma is prepared by resuspending the platelet precipitate in the plasma supernatant; all operations are carried out at low temperature. The present invention uses physical temperature control to regulate blood anticoagulation and platelet activation, avoids the addition of anticoagulants and coagulants, avoids clinical adverse reactions caused by the addition of exogenous substances, and ensures the safety of clinical use of platelet-rich plasma sex.

Description

technical field [0001] The invention belongs to the technical field of blood products and relates to a method for preparing platelet-rich plasma without exogenous additives. Background technique [0002] Platelet-rich plasma (Platelet-rich plasma, PRP) specifically refers to autologous plasma containing 4-5 times the normal human platelet concentration. Platelets are cytoplasmic fragments of megakaryocytes, a category of white blood cells, formed in the bone marrow. They lack a nucleus, but contain organelles, as well as structures such as mitochondria, microtubules, and alpha, delta, and lambda particles. Among them, α-granules contain a variety of growth factors, including: platelet-derived growth factor (PDGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), transforming growth factor ( TGF-β) and so on. PDGF can promote macrophage activation and angiogenesis, promote fibroblast proliferation activity and chemot...

AI Technical Summary

Problems solved by technology

[0004] Although the PRP prepared by the prior art has certain clinical application value, the exogenous additives such as anticoagulants and coagulants still have defects to a certain extent, such as: 1) sodium citrate can cause platelet aggregation At the same time, it will destroy platelets to a certain extent, thereby affecting the platelet count, and it is impossible to accurately obtain PRP with clinical significance. Calcium decreases, thereby showing tetany, bleeding tendency, blood pressure drop, slow heart rate and even cardiac arrest; 2) adverse reactions of thrombin, the concentration of thrombin in vitro can affect cell proliferation, tissue factor and inflammatory factor release, high It has neurotoxicity at high concentrations, inhibits cell proliferation, and even causes brain cell death

Images